<table>
<thead>
<tr>
<th>Title</th>
<th>Area of interest</th>
<th>Principal Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast Surgery</td>
<td>MED/18</td>
<td>Various</td>
</tr>
</tbody>
</table>

### Summary

**MOZART EVOLUTION**  
Principal Investigator: Prof. D. Friedman  
Prospective study of our U.O. for the intra-operative determination of the margins of exeresis in breast cancer nodular lesions by means of a comparison between the anatomical pathological evaluation and the radiological evaluation with the use of the Mozart mammography with 3D tomosynthesis.

**MOZART SUBCLINICAL LESIONS**  
Principal Investigator: Prof. D. Friedman  
Prospective study for the determination of surgical margins of non-nodular subclinical lesions (microcalcifications, parenchymal distortion) of the breast (benign and malignant) by radiological evaluation using Mozart mammography with 3D tomosynthesis technique.

**NO INK ON DCIS**  
Principal Investigator: Dott. P. Fregatti  
Retrospective study from 2010 to date to assess the oncologically correct amplitude of the DCIS resection margins.

### Multicenter Studies:

**A-BRAVE**  
Principal Investigator: Prof. L. Del Mastro  
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-11 Antibody Avelumab (A-Bra)  
Link to protocol: [https://clinicaltrials.gov/ct2/show/NCT02926196](https://clinicaltrials.gov/ct2/show/NCT02926196)

**AURORA**  
Principal Investigator: Prof. A. Ballestrero  
Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer: AURORA Screening Platform  
Link to protocol: [https://clinicaltrials.gov/ct2/show/NCT02102165](https://clinicaltrials.gov/ct2/show/NCT02102165)
BIOITALEE
CLEE011AIT01
Principal Investigator: Prof. A. Ballestrero
A phase IIIb, open-label, local, multicenter study of the molecular features of postmenopausal women with HR+ HER2- advanced breast cancer on first-line treatment with ribociclib and letrozole
Link to protocol: https://clinicaltrials.gov/ct2/show/NCT03439046

CITUCEL
Principal Investigator: Prof. A. Ballestrero
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in breast cancer patients: a prospective study

CONSENT
GIM-10
Principal Investigator: Prof. L. Del Mastro
A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatment of post-menopausal patients with endocrinoresponsive early BC
Link to protocol: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202939/

FEDERICA
WO40324
Principal Investigator: Prof. A. Ballestrero
A phase III, randomized, multicenter, open-label, two-arm study to evaluate the PK, efficacy, and safety of subcutaneous administration of the fixed-dose combination of Pertuzumab and Trastuzumab + chemotherapy in patients with HER2+ early breast cancer
Link to protocol: https://clinicaltrials.gov/ct2/show/NCT03493854

IMPASSION 030
WO39391
Principal Investigator: Prof. A. Ballestrero
A Phase III, multicenter, randomized, open-label study comparing Atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable Triple-Negative breast cancer
Link to protocol: https://ichgcp.net/clinical-trials-registry/NCT03498716

LUCY
PXL 234674
Principal Investigator: Prof. A. Ballestrero
A Phase IIIb, single-arm, open-label multicentre study of Olaparib monotherapy in the treatment of HER2- metastatic breast cancer patients with germline BRCA1/2 mutations
Link to protocol: https://clinicaltrials.gov/ct2/show/NCT03286842

monarchE
Principal Investigator: Prof. L. Del Mastro
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)
Link to protocol: https://clinicaltrials.gov/ct2/show/NCT03155997

Neo-MBCC
Principal Investigator: Prof. A. Ballestrero
Characterization of individual foci of multicentric/multifocal neoadjuvant breast cancer using targeted next generation sequencing
NEOTRIP
Principal Investigator: Prof. L. Del Mastro
Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 (NeoTRIPaPDL1)
Link to protocol: https://clinicaltrials.gov/ct2/show/NCT02620280

PALLAS
BIG 14-03
Istituto Europeo di Oncologia - Milano
PALbociclib CoLLaborative Adjuvant Study: A randomized phase III trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer

PYTHIA
BIG 14-04
Principal Investigator: Prof. G. Zoppoli
A Phase II Study of Palbociclib plus Fulvestrant for pretreated patients with ER+/HER2- Metastatic Breast Cancer

SINODAR ONE
Principal Investigator: Dr. C. Tinterri (Ist. Humanitas Rozzano)
SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes.
Link to protocol: https://www.ncbi.nlm.nih.gov/pubmed/27406897